Lefamulin最初由Nabriva开发,2018年3月仑胜医药获得在大中华区,包括中国大陆、香港、澳门、台湾开...查看全文
$Nabriva Therapeutics plc - Ordinary Shares(NBRV)$ CORRESP [Cover] - Correspondence Filed: 2018-04-25 AccNo: 0001104659-18-026641 Size: 9 KB 网页链接
$Nabriva Therapeutics plc - Ordinary Shares(NBRV)$ CORRESP [Cover] - Correspondence Filed: 2018-04-09 AccNo: 0001104659-18-023060 Size: 34 KB 网页链接
$Nabriva Therapeutics plc - Ordinary Shares(NBRV)$ CORRESP [Cover] - Correspondence Filed: 2018-04-25 AccNo: 0001104659-18-026641 Size: 9 KB 网页链接
$Nabriva Therapeutics plc - Ordinary Shares(NBRV)$ CORRESP [Cover] - Correspondence Filed: 2018-04-09 AccNo: 0001104659-18-023060 Size: 34 KB 网页链接
$Nabriva Therapeutics plc - Ordinary Shares(NBRV)$ 内部交易: 2018-05-23,CEO & Director,Broom Colin MD ,买入,10000普通股, $4.60
$Nabriva Therapeutics plc - Ordinary Shares(NBRV)$ 内部交易: 2018-05-23,Director,Webster Stephen W ,买入,8000普通股, $4.59
$Nabriva Therapeutics plc - Ordinary Shares(NBRV)$ 内部交易: 2018-05-23,CFO,Sender Gary ,买入,2000普通股, $4.57
$Nabriva Therapeutics plc - Ordinary Shares(NBRV)$ 内部交易: 2018-05-23,General Counsel & Secretary,Crotty Robert ,买入,10000普通股, $4.48
$Nabriva Therapeutics plc - Ordinary Shares(NBRV)$ 8-K - Current report Filed: 2018-05-21 AccNo: 0001104659-18-034636 Size: 4 MBItem 7.01: Regulation FD DisclosureItem 8.01: Other EventsItem 9.01: Financial Statements and Exhibits 网页链接
$Nabriva Therapeutics plc - Ordinary Shares(NBRV)$ CT ORDER - Confidential treatment order Filed: 2018-05-17 AccNo: 9999999997-18-005753 Size: 14 KB 网页链接